Pieter Sonneveld focuses on Internal medicine, Multiple myeloma, Surgery, Oncology and Bortezomib. In his study, which falls under the umbrella issue of Internal medicine, Cytarabine and Carfilzomib is strongly linked to Gastroenterology. The study incorporates disciplines such as Dexamethasone and Pathology in addition to Multiple myeloma.
His Oncology study incorporates themes from Retrospective cohort study, Regimen, Immunology and Daratumumab. He interconnects Cancer research and Multiple drug resistance in the investigation of issues within Immunology. Pieter Sonneveld works mostly in the field of Bortezomib, limiting it down to topics relating to Peripheral neuropathy and, in certain cases, Dose Modification, as a part of the same area of interest.
His main research concerns Internal medicine, Multiple myeloma, Oncology, Bortezomib and Surgery. His Internal medicine study frequently links to other fields, such as Gastroenterology. His Multiple myeloma study combines topics from a wide range of disciplines, such as Newly diagnosed and Clinical trial.
His Oncology study integrates concerns from other disciplines, such as Pomalidomide, Hazard ratio, Randomized controlled trial and Daratumumab. His studies deal with areas such as Proteasome inhibitor, Hematology and Pharmacology as well as Bortezomib. His research is interdisciplinary, bridging the disciplines of Adverse effect and Surgery.
His primary areas of investigation include Multiple myeloma, Internal medicine, Oncology, Dexamethasone and Bortezomib. Pieter Sonneveld has included themes like Cancer research and Clinical trial in his Multiple myeloma study. His work on Daratumumab, Newly diagnosed, Lenalidomide and Transplantation as part of his general Internal medicine study is frequently connected to In patient, thereby bridging the divide between different branches of science.
His work carried out in the field of Oncology brings together such families of science as Carfilzomib, Randomized controlled trial, Indirect comparison, Maintenance therapy and Monoclonal antibody. His Dexamethasone study combines topics in areas such as Refractory, Gastroenterology, Stem cell, Subgroup analysis and Bortezomib/thalidomide. His work in Bortezomib addresses subjects such as Melphalan, which are connected to disciplines such as Prednisone.
His scientific interests lie mostly in Multiple myeloma, Internal medicine, Oncology, Dexamethasone and Bortezomib. His study in the field of Daratumumab is also linked to topics like In patient. In most of his Internal medicine studies, his work intersects topics such as Gastroenterology.
His Oncology research includes elements of Ixazomib, Survival rate, Randomized controlled trial, Minimal residual disease and Monoclonal antibody. His research integrates issues of Relapsed refractory, Refractory and Cancer research in his study of Dexamethasone. He has researched Bortezomib in several fields, including Progression-free survival, First relapse and Melphalan.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
International uniform response criteria for multiple myeloma
B. G. M. Durie;J.-L. Harousseau;J. S. Miguel;J. Blade.
International staging system for multiple myeloma.
Philip R. Greipp;Jesus San Miguel;Brian G.M. Durie;John J. Crowley.
Journal of Clinical Oncology (2005)
Bortezomib or high-dose dexamethasone for relapsed multiple myeloma
Paul G. Richardson;Pieter Sonneveld;Michael W. Schuster;David Irwin.
The New England Journal of Medicine (2005)
Autologous Bone Marrow Transplantation as Compared with Salvage Chemotherapy in Relapses of Chemotherapy-Sensitive Non-Hodgkin's Lymphoma
Philip T;Guglielmi C;Hagenbeek A;Somers R.
The New England Journal of Medicine (1995)
Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group
Robert A. Kyle;J. Anthony Child;Kenneth Anderson;Bart Barlogie.
British Journal of Haematology (2003)
Revised International Staging System for Multiple Myeloma: A Report From International Myeloma Working Group
Antonio Palumbo;Hervé Avet-Loiseau;Stefania Oliva;Henk M. Lokhorst.
Journal of Clinical Oncology (2015)
International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma
Shaji Kumar;Bruno Paiva;Kenneth C. Anderson;Brian Durie.
Lancet Oncology (2016)
Daratumumab, Bortezomib, and Dexamethasone for Multiple Myeloma
Antonio Palumbo;Asher Chanan-Khan;Katja Christina Weisel;Ajay K Nooka.
The New England Journal of Medicine (2016)
Bortezomib Induction and Maintenance Treatment in Patients With Newly Diagnosed Multiple Myeloma: Results of the Randomized Phase III HOVON-65/ GMMG-HD4 Trial
Pieter Sonneveld;Ingo G.H. Schmidt-Wolf;Bronno Van Der Holt;Laila El Jarari.
Journal of Clinical Oncology (2012)
International Myeloma Working Group guidelines for serum-free light chain analysis in multiple myeloma and related disorders
A. Dispenzieri;R. Kyle;G. Merlini;J. S. Miguel.
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: